Tribio Anti-Human TIM-3 & PD-L1 Bispecific Antibody (TBS10417)

Description

Description: Tribio TIM3 & CD274 Bispecific Antibody is a modified antibody that simultaneously binds TIM-3 on immune cells and PD-L1 on tumor cells. It is designed for cancer immunology research to block two key immune checkpoint pathways at the same time, helping restore T cell activity and enhance anti-tumor immune responses. It is commonly used in studies of immune evasion, T cell exhaustion, and checkpoint combination strategies in solid tumors.

Applications: ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Species reactivity: Human

Host species: Human

Target: T-cell immunoglobulin mucin receptor 3, HAVcr-2, TIMD-3, T-cell membrane protein 3, HAVCR2, Hepatitis A virus cellular receptor 2, CD366, TIMD3, TIM-3, TIM3, T-cell immunoglobulin and mucin domain-containing protein 3, B7-H1, Programmed cell death 1 ligand 1, PDCD1 ligand 1, PDCD1L1, B7 homolog 1, PDCD1LG1, PDL1, hPD-L1, Programmed death ligand 1, B7H1, PD-L1, CD274

Isotype: IgG

Accession/UniProt: Q8TDQ0 & Q9NZQ7

Concentration: 3 mg/ml

Purity: >95%

Formulation: Liquid

Storage buffer: 0.01M PBS, pH 7.4

Purification: Protein A/G purified from cell culture supernatant.

Clonality: Monoclonal

Storage: Avoid repeated freeze-thaw cycles. -20°C for 12 months; -80°C for long-term storage.

Research use only.

Additional information